- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.06. | Jyong Biotech Ltd. Announces Closing of $20 Million Initial Public Offering | 2 | GlobeNewswire (USA) | ||
| JYONG BIOTECH Aktie jetzt für 0€ handeln | |||||
| 17.06. | Jyong Biotech Ltd. IPO opens at $15 after pricing at $7.50 per share | 2 | Investing.com | ||
| 17.06. | Taiwan's Jyong Biotech doubles in value on Nasdaq debut | 1 | Investing.com | ||
| 17.06. | Urinary disease biotech Jyong Biotech prices US IPO at $7.50, the low end of the range | 1 | Renaissance Capital | ||
| 17.06. | Jyong Biotech Prices 2.67M Share IPO at $7.50/sh | 2 | Investing.com | ||
| 17.06. | Jyong Biotech Announces Pricing Of 2.67 Mln Shares IPO At $7.50/Shr | 1 | RTTNews | ||
| 17.06. | Jyong Biotech Ltd. Announces Pricing of $20 Million Initial Public Offering | 141 | GlobeNewswire (Europe) | New Taipei City, Taiwan, June 16, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (the "Company"), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative... ► Artikel lesen | |
| 12.06. | Jyong Biotech Ltd. - 8-A12B, Registration of securities | - | SEC Filings | ||
| 11.03. | Jyong Biotech Ltd. - F-1/A, Registration statement for certain foreign private issuers | 1 | SEC Filings | ||
| 06.02. | Urinary disease biotech Jyong Biotech sets terms for $19 million US IPO | 1 | Renaissance Capital | ||
| 06.02. | Jyong Biotech Ltd. - F-1/A, Registration statement for certain foreign private issuers | - | SEC Filings |
11 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 33,610 | 0,00 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants | -- Unprecedented data from FORTITUDE dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,420 | 0,00 % | Summit Therapeutics vor Mega-Deal: Aktie +15% | Papiere von Summit Therapeutics legen heute in der Spitze um +15% zu. Vorausgegangen ist ein Bloomberg-Bericht um einen bevorstehenden Mega-Deals mit dem Pharmakonzern AstraZeneca. Laut Bloomberg News... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,280 | 0,00 % | Recursion Pharmaceuticals: Recursion Acquires Full Rights to REV102, a Potential First-in-Class Oral ENPP1 Inhibitor for Hypophosphatasia | Salt Lake City, UT, July 08, 2025 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives today announced the acquisition... ► Artikel lesen | |
| PROKIDNEY | 3,720 | 0,00 % | Pre-market Movers: Basel Medical Group, SOBR Safe, ProKidney, RxSight, Mustang Bio | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.05 A.M. ET).In the Green Basel Medical Group Ltd (BMGL) is up over 88% at... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 19,570 | 0,00 % | Structure Therapeutics Inc. - 8-K, Current Report | ||
| COGENT BIOSCIENCES | 11,100 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares | ||
| NUVALENT | 84,73 | 0,00 % | Nuvalent, Inc.: Nuvalent Announces Positive Pivotal Data from ARROS-1 Clinical Trial of Zidesamtinib for TKI Pre-treated Patients with Advanced ROS1-positive NSCLC | Aligned with FDA on NDA submission strategy for TKI pre-treated patients with advanced ROS1-positive NSCLC and participation in Real-Time Oncology Review; the... ► Artikel lesen | |
| BEAM THERAPEUTICS | 21,150 | 0,00 % | Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress | Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to Patients... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 41,620 | +6,23 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| ARCELLX | 69,86 | +1,28 % | Piper Sandler maintains Overweight rating on Arcellx stock amid CAR-T safety study | ||
| IMMUNOVANT | 18,590 | +2,48 % | Goldman Sachs nimmt Berichterstattung über Immunovant mit "Neutral"-Rating wieder auf | ||
| ARCUTIS BIOTHERAPEUTICS | 15,910 | 0,00 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., July 03, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 44,910 | +0,97 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| PRIME MEDICINE | 4,805 | 0,00 % | Prime Medicine, Inc.: Prime Medicine Announces Breakthrough Clinical Data Showing Rapid Restoration of DHR Positivity After Single Infusion of PM359, an Investigational Prime Editor for Chronic Granulomatous Disease | -- First ever clinical data supporting safety and efficacy of Prime Editing in humans -- -- Initial data from first patient dosed in Phase 1/2 trial finds single dose of PM359 led to 58% DHR positivity... ► Artikel lesen | |
| JANUX THERAPEUTICS | 26,180 | 0,00 % | Raymond James startet Coverage für Janux Therapeutics mit "Outperform"-Rating |
Das Unternehmen JYONG BIOTECH LTD kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 11,620 Euro und damit +16,08 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JYONG BIOTECH LTD finden Sie auf Wallstreet Online.